NABTC Central Operation Grant (UCSF Project Leader)
NABTC 中央运营补助金(UCSF 项目负责人)
基本信息
- 批准号:7284988
- 负责人:
- 金额:$ 65.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1994
- 资助国家:美国
- 起止时间:1994-03-25 至 2008-12-31
- 项目状态:已结题
- 来源:
- 关键词:AccountabilityAdherenceAdultAlabamaAngiogenesis InhibitorsApplications GrantsBiological Response Modifier TherapyBrainBrain NeoplasmsCaliforniaCancer CenterCancer Therapy Evaluation ProgramCentral Nervous System NeoplasmsChildhoodClinicClinicalClinical ResearchClinical TrialsCollaborationsCollectionCytotoxic agentDataData AnalysesData QualityData ReportingDatabasesDevelopmentDoctor of MedicineDrug KineticsExperimental DesignsFundingGenesGliomaGoalsGrantHumanImmuneIndustryInstitutionIntramural Research ProgramInvestigationLaboratoriesLaboratory FindingLeadLeadershipMalignant GliomaMalignant neoplasm of brainMolecular GeneticsMonitorMouse Models of Human Cancer ConsortiumNew Approaches to Brain Tumor Therapy ConsortiumNorth American Brain Tumor ConsortiumOffice of Administrative ManagementOperative Surgical ProceduresOutcomePatientsPediatric Brain Tumor ConsortiumPerformancePharmaceutical PreparationsPhasePhase I/II TrialPhase II Clinical TrialsPopulationPrincipal InvestigatorProtocols documentationPurposeQuality ControlRadiationRadiation enhancerRegulationReportingReproduction sporesResearchResourcesSan FranciscoSignal Transduction InhibitorSpecimenStandards of Weights and MeasuresSystemTechniquesTexasTherapeutic AgentsTranslational ResearchTumor BiologyU-Series Cooperative AgreementsUnited StatesUnited States Dept. of Health and Human ServicesUnited States Food and Drug AdministrationUnited States National Institutes of HealthUniversitiesUniversity of Texas M D Anderson Cancer CenterWorkcancer therapydata managementmemberneuro-oncologynovelnovel strategiesnovel therapeuticsprogramsprotocol developmenttumor
项目摘要
DESCRIPTION (provided by applicant): The North American Brain Tumor Consortium (NABTC) was formed in 1993 and has continuously conducted early phase clinical trials for patients with malignant brain tumors. The Central Operations Office/Coordinating Center for the NABTC is at the University of California San Francisco (UCSF) under the Group Leadership of Michael Prados, MD. The UCSF Central Operations Office/Coordinating Center for this renewal grant application will continue to coordinate the scientific and administrative activities of the Participating Member Institutions and Pharmacokinetics Center of the NABTC. The NABTC will be composed of 7 full Member Institutions from across the United States, a non-funded Member Institution at the NCI/NINDS Neuro-Oncology Branch, and 1 Pharmacokinetics Center at the University of Texas San Antonio. The NABTC will coordinate its efforts with the Cancer Therapy Evaluations Program (CTEP) and the Radiation Research Program (RRP) of the Division of Cancer Therapy to conduct novel therapies in this patient population. The Central Operations Office/Coordinating Center will provide administrative management, coordination of protocol development and submissions, study conduct, quality control, protocol performance monitoring, statistical analysis, adherence to requirements regarding NCI drug accountability, FDA, OHRP and HHS regulations, and protocol and institutional performance reporting. As Group Leader, Dr. Prados will oversee the scientific, clinical and administrative activities of the NABTC, with the assistance of CTEP, in order to achieve the NABTC goals. Data Management for the NABTC will continue to be supported by a subcontract with the MD Anderson Cancer Center Data Management Center. The goal of the NABTC Central Operations Office/Coordinating Center will be to assure high quality research during the conduct of ongoing and new novel clinical trials and to perform ancillary laboratory investigations of aspects of CNS tumor biology with potential clinical implications. In this renewal application, the NABTC will also plan to interact with the other funded adult (NABTT) and pediatric (PBTC) brain tumor consortia, the Mouse Models of Human Cancer Consortium, the recently funded Brain Tumor SPORE institutions (UCSF and University of Alabama), and the intramural Neuro-Oncology Branch at the NIH/NCI. The NABTC, with the assistance of the Central Operations Office/Coordinating Center, its Member Institutions and Pharmacokinetics Center, has worked well together over the last 9 years, accruing nearly 1000 patients to phase I and early phase II studies in the last 5 years, and seeks to further enhance this effort in the next 5 years. The NABTC will treat patients using novel therapeutic agents with the ultimate goal to increase quality, and hopefully, overall survival in this patient population.
描述(由申请人提供):北美脑肿瘤协会(NABTC)成立于1993年,一直为恶性脑肿瘤患者进行早期临床试验。NABTC的中央运作办公室/协调中心位于加州大学旧金山分校(UCSF),由Michael Prados博士领导。UCSF中央运作办公室/协调中心将继续协调参与NABTC的成员机构和药代动力学中心的科学和行政活动。NABTC将由来自美国各地的7个正式成员机构、NCI/NINDS神经肿瘤学分会的一个非资助成员机构和德克萨斯大学圣安东尼奥分校的1个药代动力学中心组成。NABTC将与癌症治疗部门的癌症治疗评估项目(CTEP)和放射研究项目(RRP)协调工作,在该患者群体中开展新疗法。中央业务办公室/协调中心将提供行政管理、方案制定和提交协调、研究实施、质量控制、方案绩效监测、统计分析、遵守NCI药品责任要求、FDA、OHRP和HHS法规,以及方案和机构绩效报告。作为小组组长,普拉多斯博士将在CTEP的协助下监督NABTC的科学、临床和行政活动,以实现NABTC的目标。NABTC的数据管理将继续由MD安德森癌症中心数据管理中心的分包合同提供支持。NABTC中央运营办公室/协调中心的目标是确保正在进行的和新的新颖临床试验期间的高质量研究,并对中枢神经系统肿瘤生物学方面具有潜在临床意义的辅助实验室研究。在此更新申请中,NABTC还将计划与其他资助的成人(NABTT)和儿科(PBTC)脑肿瘤联盟、人类癌症小鼠模型联盟、最近资助的脑肿瘤孢子机构(UCSF和阿拉巴马大学)以及NIH/NCI的内部神经肿瘤学分支进行互动。NABTC在中央运营办公室/协调中心、其成员机构和药代动力学中心的协助下,在过去的9年里合作良好,在过去的5年里积累了近1000名患者进行I期和早期II期研究,并寻求在未来5年进一步加强这一努力。NABTC将使用新型治疗药物治疗患者,最终目标是提高质量,并有望提高患者群体的总生存率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL D PRADOS其他文献
MICHAEL D PRADOS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL D PRADOS', 18)}}的其他基金
A PHASE I STUDY OF OSI-774 AND TEMOZOLOMIDE FOR THE TREATMENT OF GLIOMAS
OSI-774 和替莫唑胺治疗神经胶质瘤的 I 期研究
- 批准号:
7202618 - 财政年份:2005
- 资助金额:
$ 65.05万 - 项目类别:
NABTC 01-08: PHASE II TRIAL OF STI571 (NSC 716051) IN RECURRENT MENINGIOMA
NABTC 01-08:STI571 (NSC 716051) 治疗复发性脑膜瘤的 II 期试验
- 批准号:
7202661 - 财政年份:2005
- 资助金额:
$ 65.05万 - 项目类别:
ZD1839 FOR MALIGNANT ASTROCYTOMA OR GLIOBLASTOMA AND MENINGIOMA
ZD1839 用于恶性星形细胞瘤或胶质母细胞瘤和脑膜瘤
- 批准号:
7202621 - 财政年份:2005
- 资助金额:
$ 65.05万 - 项目类别:
A PHASE II TRIAL OF POLY ICLC IN PATIENTS WITH RECURRENT ANAPLASTIC GLIOMA
POLY ICLC 在复发性间变性胶质瘤患者中的 II 期试验
- 批准号:
7202656 - 财政年份:2005
- 资助金额:
$ 65.05万 - 项目类别:
A Phase II Trial of Poly ICLC in Patients with Recurrent Anaplastic Glioma
Poly ICLC 在复发性间变性胶质瘤患者中的 II 期试验
- 批准号:
6972317 - 财政年份:2004
- 资助金额:
$ 65.05万 - 项目类别:
OSI-774 in Recurrent Malignant Gliomas & Malignant Gliomas Post Radiation Tx
OSI-774 在复发性恶性胶质瘤中的应用
- 批准号:
6972313 - 财政年份:2004
- 资助金额:
$ 65.05万 - 项目类别:
Phase I/II trial of ST1571 in children with newly diagnosed brainstem gliomas
ST1571 在新诊断脑干胶质瘤儿童中的 I/II 期试验
- 批准号:
7043562 - 财政年份:2004
- 资助金额:
$ 65.05万 - 项目类别:
Phase I/II Trial of R115777 in Patients With Recurrent Malignant Glioma
R115777 在复发性恶性胶质瘤患者中的 I/II 期试验
- 批准号:
6972244 - 财政年份:2004
- 资助金额:
$ 65.05万 - 项目类别:
NABTC 01-08: Phase II Trial of STI571 (NSC 716051) in Recurrent Meningioma
NABTC 01-08:STI571 (NSC 716051) 治疗复发性脑膜瘤的 II 期试验
- 批准号:
6972320 - 财政年份:2004
- 资助金额:
$ 65.05万 - 项目类别:
ZD1839 for Malignant Astrocytoma or Glioblastoma and Meningioma
ZD1839 用于恶性星形细胞瘤或胶质母细胞瘤和脑膜瘤
- 批准号:
6972269 - 财政年份:2004
- 资助金额:
$ 65.05万 - 项目类别:
相似海外基金
Structural Racism, Pharmacy Closures and Disparities in Medication Adherence Among Older Adult Medicare Part-D Beneficiaries
结构性种族主义、药房关闭以及老年人医疗保险 D 部分受益人的药物依从性差异
- 批准号:
10568717 - 财政年份:2023
- 资助金额:
$ 65.05万 - 项目类别:
Medication Adherence and Cardio-Metabolic Control Indicators among Adult American Indians Receiving Tribal Health Services
接受部落卫生服务的成年美洲印第安人的药物依从性和心脏代谢控制指标
- 批准号:
10419967 - 财政年份:2022
- 资助金额:
$ 65.05万 - 项目类别:
Medication Adherence and Cardio-Metabolic Control Indicators among Adult American Indians Receiving Tribal Health Services
接受部落卫生服务的成年美洲印第安人的药物依从性和心脏代谢控制指标
- 批准号:
10592441 - 财政年份:2022
- 资助金额:
$ 65.05万 - 项目类别:
Leveraging Technology to Improve Medication Adherence in Adolescent and Young Adult Kidney or Liver Transplant Recipients
利用技术提高青少年和年轻肾移植或肝移植受者的药物依从性
- 批准号:
10369750 - 财政年份:2021
- 资助金额:
$ 65.05万 - 项目类别:
Leveraging Technology to Improve Medication Adherence in Adolescent and Young Adult Kidney or Liver Transplant Recipients
利用技术提高青少年和年轻肾移植或肝移植受者的药物依从性
- 批准号:
10633248 - 财政年份:2021
- 资助金额:
$ 65.05万 - 项目类别:
Leveraging Technology to Improve Medication Adherence in Adolescent and Young Adult Kidney or Liver Transplant Recipients
利用技术提高青少年和年轻肾移植或肝移植受者的药物依从性
- 批准号:
10487516 - 财政年份:2021
- 资助金额:
$ 65.05万 - 项目类别:
Mhealth for Pre-exposure Prophylaxis Adherence by Young Adult MSM
Mhealth 促进年轻 MSM 遵守暴露前预防
- 批准号:
10228564 - 财政年份:2018
- 资助金额:
$ 65.05万 - 项目类别:
Mhealth for Pre-exposure Prophylaxis Adherence by Young Adult MSM
Mhealth 促进年轻 MSM 遵守暴露前预防
- 批准号:
9347041 - 财政年份:2017
- 资助金额:
$ 65.05万 - 项目类别:
Mindfulness training with HIV-positive youth and adult family members to improve treatment adherence
对艾滋病毒呈阳性的青少年和成年家庭成员进行正念训练,以提高治疗依从性
- 批准号:
9480702 - 财政年份:2016
- 资助金额:
$ 65.05万 - 项目类别:
Mindfulness training with HIV-positive youth and adult family members to improve treatment adherence
对艾滋病毒呈阳性的青少年和成年家庭成员进行正念训练,以提高治疗依从性
- 批准号:
9906853 - 财政年份:2016
- 资助金额:
$ 65.05万 - 项目类别: